Company
TILT Biotherapeutics
- Biotech
- Headquarters:
- Helsinki, Finland
- Offices:
- West Palm Beach
Description
TILT Biotherapeutics develops oncolytic viral immunotherapies and engineered viral payloads to modify tumor microenvironments and enhance T-cell and checkpoint immunotherapies for patients with solid tumors.
Related
OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
ORCA TherapeuticsORCA Therapeutics develops oncolytic virus immunotherapies for prostate cancer, producing lead candidate ORCA-010 for treatment‑naive…
OsivaxOsivax develops oligoDOM self-assembling nanoparticle vaccines that activate T-cell and B-cell immunity for broader protection against…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
ONK TherapeuticsONK Therapeutics develops off-the-shelf, optimally engineered natural killer (NK) cell therapies combining CAR and TRAIL variant constructs…
Betaglue® TherapeuticsBetaglue® Therapeutics develops localized radiotherapeutic platforms delivering radiation directly into solid tumors, producing precision…
NeoPhoreNeoPhore develops small-molecule cancer therapeutics that briefly inhibit DNA mismatch repair, shifting MMR-proficient tumors toward an…
Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…